Another cost-effective strategy in an era of shrinking health care dollars.
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FACTORS FAVOURING ORAL ANTIMICROBIAL
STEPDOWN THERAPY Nowadays discharge plans are fom1Ulated al admission or shortly tl1ercafler in cases where the diagnosis is known. Wilh respect to infections. lrealment is orten divided inlo three phases (1). Wilhin the first 72 to 96 h of hospitalization, empirical broad spectrum therapy is often instituted in unstable patients in whom U1e infecting paU1ogen(s) is/are not iclenWlecl. Once the patient is clinically stable and the results of cultures are available. in two to four days. il is frequently possible to simplify therapy and replace more costly broad spectrum coverage with directed therapy. Ordinarily. after several more days of intrave nous therapy in hospital. patients are considered for discharge on oral therapy or home intravenous the rapy. The challenge for slepdown oral therapy is the earlier replacement of intravenous therapy creating greater opportunities lo reduce hospital slay or Lo reduce hospital costs and complications. The dictum tl1al all patients requiring hospitalization musl be sick enough lo require intravenous therapy musl be challenged. Depending on med ical n eeds . home intravenous therapy al $125 to $150 per clay and oral therapy al an average of $15 to $25 pe r day are more cost-effective than continued in-patient intravenous antibiotic therapy.
In a ddition lo shortened hospital stay. oral antibiotic therapy reduces phan11acy processing costs: oral equivalents of intravenous preparations are invariably cheaper: nursing cos ls are reduced: intravenous access devices do not need to be maintained; there is increased mobilization of lhe patient: and complications such as intravenous access infection and fluid overload a re avoided. On the other hand . less certain bioavailabilily via lhe oral route. lower serum concentrations and the need lo ensure patient comp liance are potential disadvantages of oral slepdown therapy.
THE BASIS OF STEPDOWN THERAPY
The scientific basis of stepdown therapy is centred on. first. newe r concepts or 'pharmacodynamic· antimicrobial action: second. the availability of newer oral agents with potent in vitro activity and good lo excellent b ioavailabilily lo comp lement older agents; and third , clinical trials comparing various intravenous and oral therapeutic strategies. Nevertheless , Lhe principle of lime over M IC cou ld be applied Lo slepdown oral therapy in which knowledge of in vitro activity and pharmacokinclics would allow the physician to select oral dosages and administration frequencies Lhal would mainta in b lood concentrations al or above Lhe MI C for most of the treatment interval ( Figure 1 ). In add ition Lo attainable peak concentrations. trough concentrations of antimicrobial agents would be of practical interes t. Clinical trials evaluating dosing regimens of bcta-laclams are urgently needed . In the absence of such information , practitioners should consider the selection ofbcla-laclarn agents that are well absorbed and have a longer half-life. or to administer antibiotics with the intention of ma in -PmoNALUSEO Y • DO IOT COPYiv to oral stepdown antibiotic therapy laining lime over MI C in patients switched from intravenous to oral slepdown therapy. In this way, the risk that slepdown therapy is less effective therapy will be minimized.
In contrast lo bela-lactam agents, aminoglycosides and quinolones have been found to kill bacteria in a concentration-dependent manner (8 ,9) . and uptake of aminoglycoside antibiotics by bacteria is intennittenl (8) . These observations are promoting the trend towards once-daily an1inoglycoside therapy (10-12). The practical application could be that aminoglycosides b e given once daily as part of an1bulatory/out-patienl therapy. The implications of concentration-dependent killing on optimal Ouoroquinolone dosing is unclear. However, based on the results of clinical trials , it is probable that the high pot.ency and attainable serum concentrations of well absorbed quinolones provide excellent coverage for Gram-negative infections.
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Older and newer oral agents for stepdown therapy: Shown in Table 1 are suggested oral regimens to replace intravenous therapy, bioavailability estimates. peak serum concentrations and clinical activity against common p athogens . Many of th e n ewer agents h ave potential advantages, including improved absorption, broader range of activity. belt.er tolerance and improved tissue activity.
Clinicians should first consider the use of older agents whenever possible because of cost implications both in a nd out of hospital. Within lhe penicillin group , ampicillin is moderately absorbed, whereas amoxicillin, bacampicillin and pivampicillin are highly absorbed (13, 14) . The latter two agen ts have 90% or greater bioavailability and are least likely to cause diarrhea and alter the gut microflora. Although out-patient studies have not shown a clear benefit of these agents over amoxicillin. in selected situations these agents can 47C LOUIE provide a therapeutic alternative that more closely approximates parenteral therapy (13) .
The older oral cephalosporins are well absorbed and provide adequate coverage for staphylococcal and streptococcal infections as well as treatment of common Gran1-negative pathogens. Some strains of Staphylococcus aureus. Escherichia coli and Klebsiella species may not be susceptible to achievable serum concentrations. Selective use of an isoxazolyl penicillin or a quinolone may be preferred. Newer cephalosporins such as cefurox.ime axetil provide an 'in class· therapeutic stepdown from intravenous cefurox.ime therapy. Loracarbef. yet to be marketed in Canada, is a serum-stable and well absorbed cephalosporin. providing similar coverage to that of cefuroxime axetil. Cefaclor, cefurox.ime and loracarbef are more consistenlly active against S aureus. E coli. Klebsiella species and Haem.ophilus influenzae than cephalexin. Cefaclor has been criticized for ils shorter half-life (40 to 60 mins) and in vitro serum instabilily; however. it is widely prescribed. well tolerated and clinically efTective in pediatric and ambu latory infection studies. Agents such as ceflxime. cefpodox.ime and ceflibulen provide extended Gramnegative coverage (exclusive of pseudomonas) previously unavailable in the cephalosporin class. The latter lwo are yet lo be marketed in Canada. Although cefix.ime has sufficient activity against group A streptococcal infections. S aureus activity is nol adequate.
Administering oral probenecid with selected belalaclams to retard renal elimination and thereby extending lime over Mie s is a strategy often practised by microbiology I infectious d iseases physicians ( 15, 16) . This strategy could also be more commonly used by primary care providers.
Macrolide antibiotics will likely play a greater role in slepdown therapy. The recent introduction of clarithromycin provides a therapeutic alternative for the treatment of Gran1-positive infections, upper and lower respiratory infections caused by both pyogenic and atypical pathogens. particu larly in individuals who are intolerant of erythromycin (17) . Similarly, azithromycin, an azalide compound. holds promise as a tissue active antimicrobial (18) . It is marketed in the United Stales and elsewhere bul is awaiting release in Canada. Clindamycin, more judiciously used because of concerns regarding the induction of pseudomembranous colitis. should be more widely used in selected situations in wh ich a combination of Gram -positive and anaerobic coverage is necessary, particularly in patients who may be allergic to beta-lactam agents or who are intolerant of metronidazole.
The f1uoroquinolones provide a significant advance particularly for the treatment of serious Gram-negative infections. Both ciprof1oxacin and ofloxacin should be considered as agents for stepdown therapy in hospitalized patients. replacing prolonged aminoglycoside therapy. The complications from prolonged aminoglycoside 48C lreatmenl can be avoided (19) and therapeutic drug monitoring costs are nol incurred. The focus for the use of quinolones should be directed al the lrealmenl of Gram-negative infections lo minimize the rate of induction of resistance. particularly in situations in which other therapeutic options are available.
Trimethoprim/sulfamethoxazole (TMP/SMX) and melronidazole remain 'bargain basement' therapeutic agents. which in combination provide broad spectrum therapy for common infections. In addition lo lhe lrealment of Gram-negative pathogens exclusive of Pseudom.onas ae111ginosa. TMP/SMX provides substantial coverage against Gram-positive pathogens inc luding streptococci and methicillin-susccptible S aureus (20) . TMP/SMX is also considered as an alternate lo intravenous vancomycin for the treatment of selected methicillin-resislanl S aureus infections. although increasing resistance is developing (21) . Melronidazole and imipenem have been shown on antimicrobial surveys lo be the mosl active agents against clinically imporlanl anaerobic pathogens (22) . The excellent absorption of melronidazole, its low cosl. wide disllibution in body tissues and maintenance of serum concentrations above the MIC of anaerobes even al trough concentrations support the continued use of this drug as an agenl of choice for lhe treatment of . anaerobic infections.
Stepdown lrealmenl of serious enterococcal infections is difficult since combination intravenous therapy with ampicillin plus an aminoglycoside (for aminoglycoside-susceptible strains) or vancomycin wilh or without an an1inoglycoside is recommended. Emergence of vancomycin resistance in enlerococci has eliminated all therapeutic options. F'or the present. lhe ampicillin derivatives or chloramphenicol may be selected as oral therapy for ampicillin -susceptible isolates. Ciprofloxacin and of1oxacin may also be considered . bul lhere is a dearth of data on the trealmenl of enlerococcal infections by quinolones. Clinical trials comparing intravenous with oral therapy: Third-generation cephalosporins. introduced in the 1980s. allowed physicians to avoid the use of aminoglycosides in the treatment of serious Gram-negative infections in hospitalized patients. In the mid -l 980s. il was shown lhat oral ciprof1oxacin 750 mg every 12 h was comparable with intravenous ccfotax.ime 2 g every 8 h for the treatment of Gram-negative infections in hospitalized patients (23) . Similarly. ciprof1oxacin given intravenously followed by oral therapy provided comparable clinical outcomes lo ceflazidime for lhe lrealmenl of serious Gran1 -negalive infections (24) . These studies also showed lhal S aureus infections responded suboptimally (approximately 70%) to ciprof1oxacin and cellazid ime, underscoring the need lo use antimicrobial agents with U1e best pharmacodynamic advantage. In addition, difllcull to treat infections. such as those caused by P ae111gi11osa. may require combination lher- Table 2 are several models of intravenous lo oral slepclown therapy. The specific choice for slepdown therapy depends on the specific pathogens lo be lrealecl . Oflcn, cefazolin is used lo lreal presumed staphylococcal and slreplococcal infeclions. eg. acute cellulilis. as a replacement for intravenous penicillin G and cloxacillin combined (or cloxacillin alone). Oral pcnicillin/cloxacillin could be chosen. or alternatively clindamycin. For
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coverage of mixed Gram-positive and common Gramnegalive bacilli infeclion. cefazolin could be replaced by TMP/SMX or an oral firsl-gc ncralion cephalosporin. The dosing of TMP/SMX could be al one double -slrenglh lablel twice daily. although lrealI11enl wilh higher doses is possible and perha ps desirable in serious infections (20) . ll should be recalled Uia l cephalexin is eight-lo 16-fold less a ctive lhan ceJazolin against S aure us. Therefore. while mosl palienls with staphylococcal infections will respond lo oral cephalexin. some may respond subopt.imally.
The in vilro aclivily profile or Uie other oral ccphalosporins is similar lo cephalexin. Ccfoxitin or ils replacement drugs cefolelan or ceflizoximc can be re placed by a combination of TMP/SMX and mclronidazole. Amoxicillin/clavulinic acid would also provide a similar spectrum of coverage against staphylococci, slrcplococci. common Gram-negatives and anaerobes.
The lhircl -generalion cephalosporins cefl1iaxone and cefolaxime can be replaced by a combination of Gramposilivc coverage provided by nucloxacillin or a first-generation cephalosporin plus a quinolone antimicrobial. ll should be noled lhal third-generation cephalosporin MJC90 values for S aure us arc lwo-lo fourfold higher (cefolaxime) or four-lo eightfold higher (ccflriaxone) than wilh cefazolin or cloxacillin. Although clinical studies have shown salisfaclory responses for the lrcalmenl of staphylococcal infections. mosl clinicians would opl for specific antislaphylococcal therapy. Cefixime has been recommended in some inslitulions as a slepclown alternative lo replace intravenous lhi rdgeneration cephalosporin therapy. Ceflazidime appears lo be comparable wilh ciprol1oxacin, and lhe clinical lrials support such a slepdown sequence in palienls wilh Gra m -negative and pseudomonas inJeclion. Finally. imipencm/cilislalin or clinclamycin plus ceftaziclime as broad spectrum therapy could be replaced by a combinalion of clindamycin plus ciproJloxacin for U1e none of U1ese combinalions adequately covers coagulase-negauve slaphylococcal infections involving prosU1elic devices.
CONCLUSIONS: STEPDOWN THERAPY IN THE l 990S
While physicians are being asked lo switch rapidly from intravenous lo oral or home inlravcnous therapies lo reduce heallh care cosls . il is clear Lhal lhere are informalion gaps relaling lo anlimicrobial choices. aosages and combinations. particularly wilh older agenls. Il would be desirable for heallh oulcomes research. whether funded by lhe pham1aceulical induslry or public agencies. lo evaluate cosl effective stralegies of antimicrobial lherapy. Nevertheless, lhe currenl slate of knowledge indicates lhal slepdown lherapy
